TREATMENT AND PREVENTION OF GLIOBLASTOMA

The invention relates to the use of a selective β2adrenergic receptor antagonist for treating glioma. In particular, the invention relates to the use of an alkanolamine derivative or a pharmaceutically acceptable acid-addition salt thereof for treating a glioblastoma in a patient.

Saved in:
Bibliographic Details
Main Authors BOTELLA CUBELLS, Luisa María, SÁNCHEZ-PUELLES GONZÁLEZ-CARVAJAL, José María, VILLAR GOMEZ-DE LAS HERAS, Karina, ALBIÑANA DÍAZ, Virginia, CUESTA MARTÍNEZ, Ángel, AGUADO SANCHEZ, Tania
Format Patent
LanguageEnglish
French
German
Published 07.08.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to the use of a selective β2adrenergic receptor antagonist for treating glioma. In particular, the invention relates to the use of an alkanolamine derivative or a pharmaceutically acceptable acid-addition salt thereof for treating a glioblastoma in a patient.
Bibliography:Application Number: EP20190829028